Thus, trametinib treatment of tumors in vivo caused prominent inhibition of MEK1/2 pathway activity, reduced the rate of tumor growth, and promoted stem-like characteristics of tumor cells in full concordance with results obtained in experiments in vitro. Here, MAP2K1 is linked to neoplasm.